South Korean Drug Shows Promise in Slowing Alzheimer’s

0

A South Korean drug, repurposed for Alzheimer’s, may be first to slow the disease in the U.S.

An elderly person is organizing their medication into a weekly pill organizer on a wooden table.

2 min read

A South Korean drug, originally used for erectile dysfunction, has shown potential in slowing Alzheimer’s disease, according to a recent clinical trial. The drug, known as AR1001 and sold as Mvix in South Korea, was tested in a yearlong study involving over 1,500 people with early-stage Alzheimer’s. The trial, reported by The Washington Post, indicated that the lower-dose version of the drug slowed mental decline by about 31% in participants not taking other dementia medications.

Results and Limitations

Among the roughly 40% of participants who weren’t on other dementia drugs, the treatment showed significant benefits. However, those taking other dementia medications saw little to no improvement. Overall, the trial’s results were not statistically significant when considering the entire group. Researchers assessed decline through interviews with patients and caregivers about memory, judgment, and daily life.

AriBio, the South Korean company repurposing the drug, plans to discuss the trial results with the U.S. Food and Drug Administration (FDA) to determine if additional trials are needed. If approved, the drug would be the first pill authorized in the U.S. to slow Alzheimer’s, according to Sharon Sha, a neurologist at Stanford who led the trial.

Expert Reactions and Side Effects

Sha presented the findings at the Clinical Trials on Alzheimer’s Disease conference. She emphasized the potential impact of a disease-modifying drug with minimal side effects and oral administration. Reported side effects included diarrhea, dizziness, falls, and fainting.

Richard Oakley of the Alzheimer’s Society in the UK praised the results, calling them an exciting sign of a new treatment for early Alzheimer’s. He noted the drug’s novel approach of relaxing blood vessels to increase brain blood flow, which could simplify treatment compared to other disease-modifying drugs.

Repurposing and Testing

AriBio has been testing the drug since late 2022 at a daily dose of 30 milligrams, significantly lower than the 100-milligram dose used for erectile dysfunction. The trial highlights the potential of repurposing existing drugs for new medical applications, offering hope for more accessible and effective treatments for Alzheimer’s.

Source: Daily Wire

Written by
Ryan Wilson

Leave a Reply

Your email address will not be published. Required fields are marked *